Day: March 7, 2022

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1148-79-4,2,2′:6′,2”-Terpyridine,as a common compound, the synthetic route is as follows.

Solid [Co(H2O)6](ClO4)2 (10.0 mg, 21.8 lmol) was placed at thebottom of a 4.0 cm3 test tube with 0.50 cm3 of dmso. Then the tubewas slowly filled with 2.50 cm3 of a dmso?CH3OH mixture (1:4 v/v)containing terpy (15.0 mg, 64.4 lmol). Finally, 1 (15.0 mg,9.01 lmol) dissolved in 0.50 cm3 of CH3OH was placed on the topand the tube covered with parafilm. X-ray quality deep browncrystals of 2 were grown in the text tube by slow diffusion at roomtemperature during 25 days. Yield: 3.20 mg (1.30 lmol, 29percent). X-rayabsorption microanalysis for 2: 3:2 Co/Nb molar ratio. Elementalanalysis for C105H86N18O33Co3Nb2 (2490.52 g mol1) ? Exp. (Calc.):percentC 51.55 (50.94), percentH 3.02 (3.18), percentN 10.49 (10.32), percentCo 7.50 (7.30)percent.IR (KBr disk/cm1): 3475 [m(O?H)], 3062 and 2930 [m(C?H)], 1715and 1687 [mas(CO)], 1641 [m(CN)], 1470 and 1448 [m(CC)],1401 [ms(CO)], 905 [m(NbO] and 421 [m(CoAN)].

1148-79-4, The synthetic route of 1148-79-4 has been constantly updated, and we look forward to future research findings.

Reference：
Article; Oliveira, Willian X.C.; Pereira, Cynthia L.M.; Pinheiro, Carlos B.; Krambrock, Klaus; Grancha, Thais; Moliner, Nicolas; Lloret, Francesc; Julve, Miguel; Polyhedron; vol. 117; (2016); p. 710 – 717;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1148-79-4,2,2′:6′,2”-Terpyridine,as a common compound, the synthetic route is as follows.

Solid [Co(H2O)6](ClO4)2 (10.0 mg, 21.8 lmol) was placed at thebottom of a 4.0 cm3 test tube with 0.50 cm3 of dmso. Then the tubewas slowly filled with 2.50 cm3 of a dmso?CH3OH mixture (1:4 v/v)containing terpy (15.0 mg, 64.4 lmol). Finally, 1 (15.0 mg,9.01 lmol) dissolved in 0.50 cm3 of CH3OH was placed on the topand the tube covered with parafilm. X-ray quality deep browncrystals of 2 were grown in the text tube by slow diffusion at roomtemperature during 25 days. Yield: 3.20 mg (1.30 lmol, 29percent). X-rayabsorption microanalysis for 2: 3:2 Co/Nb molar ratio. Elementalanalysis for C105H86N18O33Co3Nb2 (2490.52 g mol1) ? Exp. (Calc.):percentC 51.55 (50.94), percentH 3.02 (3.18), percentN 10.49 (10.32), percentCo 7.50 (7.30)percent.IR (KBr disk/cm1): 3475 [m(O?H)], 3062 and 2930 [m(C?H)], 1715and 1687 [mas(CO)], 1641 [m(CN)], 1470 and 1448 [m(CC)],1401 [ms(CO)], 905 [m(NbO] and 421 [m(CoAN)].

1148-79-4, The synthetic route of 1148-79-4 has been constantly updated, and we look forward to future research findings.

Reference：
Article; Oliveira, Willian X.C.; Pereira, Cynthia L.M.; Pinheiro, Carlos B.; Krambrock, Klaus; Grancha, Thais; Moliner, Nicolas; Lloret, Francesc; Julve, Miguel; Polyhedron; vol. 117; (2016); p. 710 – 717;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

118949-61-4, 2,6-Bis((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: (R)-LiPr (50mg, 0.17mmol) was dissolved in acetonitrile (15cm3). Zinc(II) tetrafluoroborate hydrate (20mg, 0.083mmol) was then added and the solution stirred at room temperature for one hour. A large excess of diethyl ether was added and the resultant precipitate was isolated by vacuum filtration leaving a white powder. Single crystals suitable for X-ray diffraction analysis were grown by vapour diffusion of diethyl ether into a concentrated solution of the product in acetonitrile. Yield: 0.054g, 78%., 118949-61-4

The synthetic route of 118949-61-4 has been constantly updated, and we look forward to future research findings.

Reference：
Article; Burrows, Kay E.; Kulmaczewski, Rafal; Cespedes, Oscar; Barrett, Simon A.; Halcrow, Malcolm A.; Polyhedron; vol. 149; (2018); p. 134 – 141;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

71071-46-0, Dimethyl [2,2′-bipyridine]-4,4′-dicarboxylate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

71071-46-0, General procedure: A solution of compound 5 (400mg, 0.822mmol), [(eta6-p-cymene) RuCl2]2 (252mg, 0.411mmol), and Me4NCl (450mg, 4.11mmol) in anhydrous acetone (21mL) was stirred under a dark atmosphere at room temperature for 6h. The reaction mixture was filtered and the filtrate was evaporated to afford crude compound as a bright orange solid. The above intermediate (200mg, 0.373mmol), dimethyl 2,2?-bipyridine-4,4?-dicarboxylate (203mg, 0.746mmol), and potassium hexafluorophosphate (103mg, 0.56mmol) were dissolved in dry 1,2-dichloroethane (20mL) and the mixture was stirred at 60°C for 12h. The mixture was then concentrated under reduced pressure and the resulting crude product was purified by column chromatography using ethyl acetate/ dichloromethane (1:1) to give compound 6 as a dark red solid (233mg, 70percent). 1H NMR (300MHz, CDCl3): delta 8.89 (s, 1H), 8.85 (s, 1H), 8.79 (s, 1H), 8.74 (s, 1H), 8.39 (d, J=5.7Hz, 1H), 8.00?7.91 (m, 3H), 7.82 (m, 3H), 7.67 (dd, J=3.6Hz, 1.5Hz, 1H), 7.52 (dt, J=8.7Hz, 1.2Hz, 1H), 7.46 (d, J=7.5Hz, 1H), 7.32?7.19 (m, 5H), 7.13 (d, J=5.7Hz, 1H), 6.72 (dt, J=6.5Hz, 1.5Hz, 1H), 3.95 (s, 3H), 3.94 (s, 3H), 3.93 (s, 3H), 3.91 (s, 3H), 1.27 (s, 3H); 13C NMR (125MHz, CDCl3): delta 192.8, 164.6, 164.4, 164.2, 162.6, 157.9, 157.8, 156.5, 156.3, 155.6, 151.9, 151.4, 150.5, 149.8, 142.5, 142.4, 138.4, 137.3, 136.6, 135.6, 135.3, 135.0, 134.9, 129.4, 128.5, 127.9, 127.6, 126.3, 162.2, 125.8, 123.0, 122.9, 122.4, 120.4, 118.8, 53.6, 53.5, 53.4, 53.3, 15.5; HRMS (FAB):calcd. for C44H36N5O8RuS [M+] 896.1328, found 896.1321.

As the paragraph descriping shows that 71071-46-0 is playing an increasingly important role.

Reference：
Article; Li, Chung-Yen; Su, Chaochin; Wang, Hsiou-Hsuan; Kumaresan, Prabakaran; Hsu, Chia-Hsuan; Lee, I-Ting; Chang, Wei-Chun; Tingare, Yogesh S.; Li, Ting-Yu; Lin, Chia-Feng; Li, Wen-Ren; Dyes and Pigments; vol. 100; 1; (2014); p. 57 – 65;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.15862-19-8,5-Bromo-2,2′-bipyridine,as a common compound, the synthetic route is as follows.,15862-19-8

5-bromo-2,2-bipyridine (0.480 g, 2 mmol), 2-methylthiophene (0.401 g, 4 mmol) and KOAc (0.401 g, 4 mmol) in dryDMA (5 mL) were stirred under N2 at 150 C for 20 h in thepresence of Pd(OAc)2 (0.009 g, 2 mol%). After cooling the solution to room temperature, CH2Cl2 (15 mL) and an aqueoussaturated NH4Cl solution (10 mL) were added. The reactionsolution was extracted three times with 15 mL of CH2Cl2, andthe combined organic layers were washed three times with 10mL of water. The solvent was evaporated under reduced pressure, and the crude product was purified by using columnchromatography (silica; 5:1 v/v hexane:EtOAc) to afford compound 1 in 22% yield (111 mg). 1H NMR (CDCl3, 500 MHz): 8.89 (dd, 1H, J = 2.3 and 0.6 Hz, ArH), 8.68 (ddd, 1H, J = 4.7,1.7 and 0.8 Hz, ArH), 8.448.36 (m, 2H, ArH), 7.93 (dd, 1H,J = 8.3 and 2.4 Hz, ArH), 7.82 (td, 1H, J = 7.8 and 1.8 Hz,ArH), 7.30 (ddd, 1H, J = 7.4, 4.8 and 1.1 Hz, ArH), 7.24(d, 1H, J = 3.5 Hz, ArH), 6.826.77 (m, 1H, ArH), 2.54 (s,3H, ArCH3) ppm. HR-MS (ESI+) m/z [M + H]+ calcd. for[C15H13N2S]+ 253.0799; found: 253.0803.

As the paragraph descriping shows that 15862-19-8 is playing an increasingly important role.

Reference：
Article; Kamila, Mritunjoy; Cosquer, Goulven; Breedlove, Brian K.; Yamashita, Masahiro; Bulletin of the Chemical Society of Japan; vol. 90; 5; (2017); p. 595 – 603;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI